ImmunovantInc Free Cash Flow per Share vs Return on Average Equity Analysis

IMVT Stock  USD 31.68  0.84  2.58%   
Trend analysis of ImmunovantInc balance sheet accounts such as Total Stockholder Equity of 241.3 M or Net Tangible Assets of 242.7 M provides information on ImmunovantInc's total assets, liabilities, and equity, which is the actual value of ImmunovantInc to its prevalent stockholders. By breaking down trends over time using ImmunovantInc balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.

About ImmunovantInc Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ImmunovantInc at a specified time, usually calculated after every quarter, six months, or one year. ImmunovantInc Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ImmunovantInc and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ImmunovantInc currently owns. An asset can also be divided into two categories, current and non-current.

ImmunovantInc Balance Sheet Chart

ImmunovantInc Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how ImmunovantInc uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, ImmunovantInc's Short Term Debt is comparatively stable compared to the past year. Capital Lease Obligations is likely to gain to about 1.9 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 242.7 M in 2024.

Total Assets

Total assets refers to the total amount of ImmunovantInc assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ImmunovantInc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ImmunovantInc balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ImmunovantInc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents ImmunovantInc obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ImmunovantInc are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.
Most indicators from ImmunovantInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmunovantInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.At this time, ImmunovantInc's Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 78.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 30.1 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses156.0M208.3M239.5M123.8M
Research Development101.8M160.3M184.3M98.9M

ImmunovantInc fundamental ratios Correlations

0.891.01.00.560.910.910.91.00.710.830.92-0.9-0.98-0.881.00.920.921.00.20.980.020.970.73-0.91.0
0.890.890.890.430.980.991.00.890.610.980.74-0.86-0.91-0.980.910.740.840.910.10.940.00.940.91-0.890.91
1.00.891.00.560.910.910.91.00.710.820.93-0.9-0.98-0.881.00.930.911.00.190.970.020.970.72-0.91.0
1.00.891.00.560.910.910.91.00.710.820.93-0.9-0.98-0.881.00.930.911.00.190.970.010.970.72-0.91.0
0.560.430.560.560.350.360.440.560.360.220.52-0.41-0.57-0.310.560.520.390.560.910.430.00.430.02-0.380.55
0.910.980.910.910.351.00.990.910.660.980.81-0.88-0.93-0.970.930.810.860.93-0.010.95-0.010.940.92-0.910.93
0.910.990.910.910.361.00.990.910.630.980.8-0.86-0.93-0.980.930.80.840.930.00.95-0.060.950.93-0.890.93
0.91.00.90.90.440.990.990.910.630.970.76-0.87-0.92-0.980.920.760.840.920.10.940.00.940.9-0.90.92
1.00.891.01.00.560.910.910.910.70.830.92-0.9-0.98-0.881.00.920.921.00.20.980.020.970.73-0.91.0
0.710.610.710.710.360.660.630.630.70.570.76-0.89-0.75-0.540.720.780.840.720.080.690.590.60.46-0.880.72
0.830.980.820.820.220.980.980.970.830.570.67-0.83-0.84-0.980.840.670.810.84-0.110.910.010.90.98-0.870.84
0.920.740.930.930.520.810.80.760.920.760.67-0.81-0.94-0.720.931.00.790.930.140.85-0.050.820.57-0.810.93
-0.9-0.86-0.9-0.9-0.41-0.88-0.86-0.87-0.9-0.89-0.83-0.810.910.83-0.9-0.82-0.98-0.9-0.07-0.92-0.4-0.87-0.731.0-0.9
-0.98-0.91-0.98-0.98-0.57-0.93-0.93-0.92-0.98-0.75-0.84-0.940.910.89-0.99-0.94-0.88-0.99-0.2-0.95-0.01-0.94-0.740.91-0.99
-0.88-0.98-0.88-0.88-0.31-0.97-0.98-0.98-0.88-0.54-0.98-0.720.830.89-0.89-0.72-0.82-0.890.04-0.940.07-0.95-0.940.86-0.89
1.00.911.01.00.560.930.930.921.00.720.840.93-0.9-0.99-0.890.930.911.00.190.980.010.970.74-0.911.0
0.920.740.930.930.520.810.80.760.920.780.671.0-0.82-0.94-0.720.930.80.930.140.85-0.010.820.57-0.820.93
0.920.840.910.910.390.860.840.840.920.840.810.79-0.98-0.88-0.820.910.80.910.060.940.390.90.71-0.970.91
1.00.911.01.00.560.930.930.921.00.720.840.93-0.9-0.99-0.891.00.930.910.190.980.010.970.74-0.911.0
0.20.10.190.190.91-0.010.00.10.20.08-0.110.14-0.07-0.20.040.190.140.060.190.060.040.08-0.31-0.040.18
0.980.940.970.970.430.950.950.940.980.690.910.85-0.92-0.95-0.940.980.850.940.980.060.070.990.83-0.930.98
0.020.00.020.010.0-0.01-0.060.00.020.590.01-0.05-0.4-0.010.070.01-0.010.390.010.040.07-0.03-0.07-0.370.01
0.970.940.970.970.430.940.950.940.970.60.90.82-0.87-0.94-0.950.970.820.90.970.080.99-0.030.84-0.880.97
0.730.910.720.720.020.920.930.90.730.460.980.57-0.73-0.74-0.940.740.570.710.74-0.310.83-0.070.84-0.780.74
-0.9-0.89-0.9-0.9-0.38-0.91-0.89-0.9-0.9-0.88-0.87-0.811.00.910.86-0.91-0.82-0.97-0.91-0.04-0.93-0.37-0.88-0.78-0.91
1.00.911.01.00.550.930.930.921.00.720.840.93-0.9-0.99-0.891.00.930.911.00.180.980.010.970.74-0.91
Click cells to compare fundamentals

ImmunovantInc Account Relationship Matchups

ImmunovantInc fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets109.4M412.5M515.6M405.8M466.7M264.7M
Total Current Liabilities15.3M18.8M44.5M43.3M49.8M52.3M
Total Stockholder Equity94.1M391.5M469.8M362.5M416.9M241.3M
Net Tangible Assets94.1M391.5M469.8M362.5M416.9M242.7M
Accounts Payable1.2M2.4M18.6M1.4M1.6M1.5M
Common Stock Shares Outstanding43.2M87.8M109.7M123.1M141.5M148.6M
Other Stockholder Equity185.3M590.4M824.8M928.0M1.1B1.1B
Total Liab15.3M21.0M45.7M43.3M49.8M52.3M
Total Current Assets109.1M409.0M512.9M404.3M465.0M263.2M
Short Long Term Debt Total3.2M3.4M2.4M1.2M1.4M2.3M
Other Current Liab14.1M15.2M24.7M40.8M46.9M49.2M
Property Plant And Equipment Net65K3.5M2.6M1.5M1.7M1.7M
Net Debt(97.4M)(396.7M)(491.5M)(375.3M)(337.8M)(354.7M)
Retained Earnings(91.2M)(198.7M)(355.4M)(566.3M)(509.7M)(484.2M)
Cash100.6M400.1M493.8M376.5M433.0M301.7M
Non Current Assets Total311K3.5M2.6M1.5M1.7M1.8M
Cash And Short Term Investments100.6M400.1M493.8M376.5M433.0M301.7M
Net Receivables3.0M548K12.9M885K1.0M966.9K
Common Stock Total Equity5K10K12K13K15.0K8.9K
Liabilities And Stockholders Equity109.4M412.5M515.6M405.8M466.7M317.6M
Non Current Liabilities Total14.1M2.2M1.2M47K42.3K40.2K
Capital Surpluse185.3M590.4M824.8M928.0M1.1B556.3M
Other Current Assets5.5M8.3M6.3M26.9M31.0M32.5M
Net Invested Capital94.1M391.5M469.8M362.5M416.9M290.0M
Capital Stock5K10K12K13K15.0K8.9K
Net Working Capital93.8M390.2M468.4M361.0M415.2M288.9M
Short Term Debt3.2M1.2M1.1M1.2M1.1M1.1M
Common Stock5K10K12K13K15.0K8.9K
Property Plant Equipment65K201K330K333K383.0K216.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether ImmunovantInc is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ImmunovantInc Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Immunovantinc Stock. Highlighted below are key reports to facilitate an investment decision about Immunovantinc Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for ImmunovantInc Stock analysis

When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
FinTech Suite
Use AI to screen and filter profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Money Managers
Screen money managers from public funds and ETFs managed around the world
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.81)
Return On Assets
(0.27)
Return On Equity
(0.45)
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.